Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1191

1.

Revealing exciton masses and dielectric properties of monolayer semiconductors with high magnetic fields.

Goryca M, Li J, Stier AV, Taniguchi T, Watanabe K, Courtade E, Shree S, Robert C, Urbaszek B, Marie X, Crooker SA.

Nat Commun. 2019 Sep 13;10(1):4172. doi: 10.1038/s41467-019-12180-y.

PMID:
31519909
2.

Entomopathogenic nematodes increase predation success by inducing cadaver volatiles that attract healthy herbivores.

Zhang X, Machado RA, Doan CV, Arce CC, Hu L, Robert CA.

Elife. 2019 Sep 11;8. pii: e46668. doi: 10.7554/eLife.46668.

3.

Estrous cycle impacts miRNA content in extracellular vesicles that modulate bovine cumulus cell transcripts during in vitro maturation.

de Ávila ACFCM, Bridi A, Andrade GM, Del Collado M, Sangalli JR, Nociti RP, da Silva Junior WA, Bastien A, Robert C, Meirelles FV, Perecin F, da Silveira JC.

Biol Reprod. 2019 Sep 2. pii: ioz177. doi: 10.1093/biolre/ioz177. [Epub ahead of print]

PMID:
31504242
4.

Control of the Exciton Radiative Lifetime in van der Waals Heterostructures.

Fang HH, Han B, Robert C, Semina MA, Lagarde D, Courtade E, Taniguchi T, Watanabe K, Amand T, Urbaszek B, Glazov MM, Marie X.

Phys Rev Lett. 2019 Aug 9;123(6):067401. doi: 10.1103/PhysRevLett.123.067401.

PMID:
31491178
5.

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.

Gogas HJ, Flaherty KT, Dummer R, Ascierto PA, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Sileni VC, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Gollerkeri A, Pickard MD, Robert C.

Eur J Cancer. 2019 Aug 19;119:97-106. doi: 10.1016/j.ejca.2019.07.016. [Epub ahead of print]

6.

Mediator in the Embryo-endometrium Cross-talk: Granulocyte Colony-stimulating Factor in Infertility.

Robert CA, Abbas MK, Zaidi ARZ, Thiha S, Malik BH.

Cureus. 2019 Aug 15;11(8):e5390. doi: 10.7759/cureus.5390. Review.

7.

Risk-based stratification in head and neck mucosal melanoma.

Moya-Plana A, Mangin D, Dercle L, Taouachi R, Casiraghi O, Ammari S, Nguyen F, Temam S, Robert C, Gorphe P.

Oral Oncol. 2019 Aug 9;97:44-49. doi: 10.1016/j.oraloncology.2019.07.026. [Epub ahead of print]

PMID:
31421470
8.

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.

Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, Vaysse T, Marthey L, Eggermont A, Asvatourian V, Lanoy E, Mateus C, Robert C, Carbonnel F.

Ann Oncol. 2019 Aug 13. pii: mdz224. doi: 10.1093/annonc/mdz224. [Epub ahead of print] No abstract available.

PMID:
31408090
9.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalá M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ.

Ann Oncol. 2019 Aug 13. pii: mdz221. doi: 10.1093/annonc/mdz221. [Epub ahead of print] No abstract available.

PMID:
31406976
10.

Gene Therapy for Parkinson's Disease: Preclinical Evaluation of Optimally Configured TH:CH1 Fusion for Maximal Dopamine Synthesis.

Badin RA, Binley K, Van Camp N, Jan C, Gourlay J, Robert C, Gipchtein P, Fayard A, Stewart H, Ralph GS, Lad Y, Kelleher M, Loader J, Hosomi K, Palfi S, Mitrophanous KA, Hantraye P.

Mol Ther Methods Clin Dev. 2019 Jul 16;14:206-216. doi: 10.1016/j.omtm.2019.07.002. eCollection 2019 Sep 13.

11.

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.

Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbe C, Ferraresi V, Smylie M, Weber JS, Maio M, Hosein F, de Pril V, Kicinski M, Suciu S, Testori A.

Eur J Cancer. 2019 Aug 7;119:1-10. doi: 10.1016/j.ejca.2019.07.001. [Epub ahead of print]

PMID:
31400634
12.

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study.

Tison A, Quéré G, Misery L, Funck-Brentano E, Danlos FX, Routier E, Robert C, Loriot Y, Lambotte O, Bonniaud B, Scalbert C, Maanaoui S, Lesimple T, Martinez S, Marcq M, Chouaid C, Dubos C, Brunet-Possenti F, Stavris C, Chiche L, Beneton N, Mansard S, Guisier F, Doubre H, Skowron F, Aubin F, Zehou O, Roge C, Lambert M, Pham-Ledard A, Beylot-Barry M, Veillon R, Kramkimel N, Giacchero D, Quatrebarbes J, Michel C, Auliac JB, Gonzales G, Decroisette C, Le Garff G, Carpiuc I, Vallerand H, Nowak E, Cornec D, Kostine M; Groupe de Cancérologie Cutanée (GCC), Groupe Français de Pneumo-Cancérologie (GFPC), Club Rhumatismes et Inflammations (CRI).

Arthritis Rheumatol. 2019 Aug 5. doi: 10.1002/art.41068. [Epub ahead of print]

PMID:
31379105
13.

Self-medication in pain management: The state of the art of pharmacists' role for optimal Over-The-Counter analgesic use.

Perrot S, Cittée J, Louis P, Quentin B, Robert C, Milon JY, Bismut H, Baumelou A.

Eur J Pain. 2019 Jul 26. doi: 10.1002/ejp.1459. [Epub ahead of print] Review.

PMID:
31349370
14.

Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics.

Seban RD, Nemer JS, Marabelle A, Yeh R, Deutsch E, Ammari S, Moya-Plana A, Mokrane FZ, Gartrell RD, Finkel G, Barker L, Bigorgne AE, Schwartz LH, Saenger Y, Robert C, Dercle L.

Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2298-2310. doi: 10.1007/s00259-019-04411-7. Epub 2019 Jul 25.

PMID:
31346755
15.

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.

Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, Larkin JMG, Lorigan P, Neyns B, Blank CU, Petrella TM, Hamid O, Su SC, Krepler C, Ibrahim N, Long GV.

Lancet Oncol. 2019 Sep;20(9):1239-1251. doi: 10.1016/S1470-2045(19)30388-2. Epub 2019 Jul 22.

PMID:
31345627
16.

Estimating health state utility from activities of daily living in the French National Hospital Discharge Database: a feasibility study with head and neck cancer.

Schwarzinger M, Luchini S; EPICORL Study Group.

Health Qual Life Outcomes. 2019 Jul 25;17(1):129. doi: 10.1186/s12955-019-1195-9.

17.

Acute pancreatitis after vismodegib for basal cell carcinoma: a causal relation?

Velter C, Blanc J, Robert C.

Eur J Cancer. 2019 Sep;118:67-69. doi: 10.1016/j.ejca.2019.06.010. Epub 2019 Jul 17. No abstract available.

PMID:
31325874
18.

Seroprevalence of hepatitis B virus co-infection among HIV-1-positive patients in North-Central Nigeria: The urgent need for surveillance.

Akindigh TM, Joseph AO, Robert CO, Okojokwu OJ, Okechalu JN, Anejo-Okopi JA.

Afr J Lab Med. 2019 Jun 27;8(1):622. doi: 10.4102/ajlm.v8i1.622. eCollection 2019.

19.

Utility of enhanced CT for patients with suspected uncomplicated renal colic and no acute findings on non-enhanced CT.

Robert C, Gandon Y, Peyronnet B, Gauthier S, Aubé C, Paisant A.

Clin Radiol. 2019 Oct;74(10):813.e11-813.e18. doi: 10.1016/j.crad.2019.06.007. Epub 2019 Jul 9.

PMID:
31300208
20.

Unraveling the effects of the gut microbiota composition and function on horse endurance physiology.

Plancade S, Clark A, Philippe C, Helbling JC, Moisan MP, Esquerré D, Moyec LL, Robert C, Barrey E, Mach N.

Sci Rep. 2019 Jul 3;9(1):9620. doi: 10.1038/s41598-019-46118-7.

21.

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA; International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV.

Lancet Oncol. 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8. Review.

PMID:
31267972
22.

A First Step Toward Unraveling the Energy Metabolism in Endurance Horses: Comparison of Plasma Nuclear Magnetic Resonance Metabolomic Profiles Before and After Different Endurance Race Distances.

Le Moyec L, Robert C, Triba MN, Bouchemal N, Mach N, Rivière J, Zalachas-Rebours E, Barrey E.

Front Mol Biosci. 2019 Jun 12;6:45. doi: 10.3389/fmolb.2019.00045. eCollection 2019.

23.

Kiss and Run: Promoting Effective and Targeted Cellular Uptake of a Drug Delivery Vehicle Composed of an Integrin-Targeting Diketopiperazine Peptidomimetic and a Cell-Penetrating Peptide.

Feni L, Parente S, Robert C, Gazzola S, Arosio D, Piarulli U, Neundorf I.

Bioconjug Chem. 2019 Jul 17;30(7):2011-2022. doi: 10.1021/acs.bioconjchem.9b00292. Epub 2019 Jun 19.

PMID:
31243977
24.

Correlated Induction of Phytohormones and Glucosinolates Shapes Insect Herbivore Resistance of Cardamine Species Along Elevational Gradients.

Robert CAM, Pellissier L, Moreira X, Defossez E, Pfander M, Guyer A, van Dam NM, Rasmann S.

J Chem Ecol. 2019 Jul;45(7):638-648. doi: 10.1007/s10886-019-01084-2. Epub 2019 Jun 22.

PMID:
31227972
25.

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.

Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob JJ, Kim TM, Demidov L, Robert C, Larkin J, Anderson JR, Maleski J, Jones M, Diede SJ, Mitchell TC.

Lancet Oncol. 2019 Aug;20(8):1083-1097. doi: 10.1016/S1470-2045(19)30274-8. Epub 2019 Jun 17.

PMID:
31221619
26.

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Lupinacci R, Krepler C, Ibrahim N, Kicinski M, Marreaud S, van Akkooi AC, Suciu S, Robert C.

Eur J Cancer. 2019 Jul;116:148-157. doi: 10.1016/j.ejca.2019.05.020. Epub 2019 Jun 11.

PMID:
31200321
27.

Stereoselective Ring-Opening (Co)polymerization of β-Butyrolactone and ε-Decalactone Using an Yttrium Bis(phenolate) Catalytic System.

Kiriratnikom J, Robert C, Guérineau V, Venditto V, Thomas CM.

Front Chem. 2019 May 22;7:301. doi: 10.3389/fchem.2019.00301. eCollection 2019.

28.

Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma.

Moya-Plana A, Herrera Gómez RG, Rossoni C, Dercle L, Ammari S, Girault I, Roy S, Scoazec JY, Vagner S, Janot F, Eggermont AMM, Robert C.

Cancer Immunol Immunother. 2019 Jul;68(7):1171-1178. doi: 10.1007/s00262-019-02351-7. Epub 2019 Jun 7.

PMID:
31172258
29.

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandalá M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV.

N Engl J Med. 2019 Aug 15;381(7):626-636. doi: 10.1056/NEJMoa1904059. Epub 2019 Jun 4.

PMID:
31166680
30.

Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy.

Seban RD, Robert C, Dercle L, Yeh R, Dunant A, Reuze S, Schernberg A, Sun R, Mignot F, Terroir M, Schlumberger M, Haie-Meder C, Chargari C, Deutsch E.

Oncoimmunology. 2019 Mar 6;8(5):e1574197. doi: 10.1080/2162402X.2019.1574197. eCollection 2019.

31.

Lactimicrobium massiliense gen. nov., sp. nov.; Anaerolactibacter massiliensis gen. nov., sp. nov.; Galactobacillus timonensis gen. nov., sp. nov. and Acidipropionibacterium timonense sp. nov. isolated from breast milk from healthy breastfeeding African women.

Togo AH, Diop A, Camara A, Kuete E, Konate S, Brevaut V, Des Robert C, Delerce J, Armstrong N, Roussel Y, Fournier PE, Thera MA, Raoult D, Million M.

New Microbes New Infect. 2019 Mar 23;29:100537. doi: 10.1016/j.nmni.2019.100537. eCollection 2019 May.

32.

Melanoma during fingolimod treatment for multiple sclerosis.

Velter C, Thomas M, Cavalcanti A, Bastien M, Chochon F, Lubetzki C, Routier E, Robert C.

Eur J Cancer. 2019 May;113:75-77. doi: 10.1016/j.ejca.2019.03.011. Epub 2019 Apr 12. No abstract available.

PMID:
30986706
33.

Post-shingles granulomatous dermatosis related to anti-programmed cell death 1.

Assi T, Danu A, Mateus C, Robert C, Michot JM, Ibrahim T, Lazarovici J, Ghez D, Rossignol J, Dartigues P, Terroir-Cassou-Mounat M, Ribrag V.

Immunotherapy. 2019 May;11(7):591-598. doi: 10.2217/imt-2018-0169.

PMID:
30943861
34.

Reply to E. Hindié and K.R. Hess.

Long GV, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Hauschild A.

J Clin Oncol. 2019 May 20;37(15):1356-1358. doi: 10.1200/JCO.19.00004. Epub 2019 Apr 2. No abstract available.

PMID:
30939092
35.

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.

Schadendorf D, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Lesimple T, Plummer R, Schachter J, Dasgupta K, Manson S, Koruth R, Mookerjee B, Kefford R, Dummer R, Kirkwood JM, Long GV.

Lancet Oncol. 2019 May;20(5):701-710. doi: 10.1016/S1470-2045(18)30940-9. Epub 2019 Mar 27.

PMID:
30928620
36.

Familial predisposition to TP53/complex karyotype MDS and leukemia in DNA repair-deficient xeroderma pigmentosum.

Sarasin A, Quentin S, Droin N, Sahbatou M, Saada V, Auger N, Boursin Y, Dessen P, Raimbault A, Asnafi V, Schmutz JL, Taïeb A, Menck CFM, Rosselli F, La Rochelle LD, Robert C, Sicre de Fontbrune F, Sébert M, Leblanc T, Kannouche P, De Botton S, Solary E, Soulier J.

Blood. 2019 Jun 20;133(25):2718-2724. doi: 10.1182/blood-2019-01-895698. Epub 2019 Mar 26. No abstract available.

37.

Polymerization of rac-Lactide Using Achiral Iron Complexes: Access to Thermally Stable Stereocomplexes.

Marin P, Tschan MJ, Isnard F, Robert C, Haquette P, Trivelli X, Chamoreau LM, Guérineau V, Del Rosal I, Maron L, Venditto V, Thomas CM.

Angew Chem Int Ed Engl. 2019 Sep 2;58(36):12585-12589. doi: 10.1002/anie.201903224. Epub 2019 Apr 12.

PMID:
30908800
38.

Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology.

Heinzerling L, Ascierto PA, Dummer R, Gogas H, Grob JJ, Lebbe C, Long GV, McArthur G, Moslehi JJ, Neilan TG, Ribas A, Robert C, Schadendorf D, Wolchok JD, Hauschild A.

Eur J Cancer. 2019 May;112:29-31. doi: 10.1016/j.ejca.2019.01.015. Epub 2019 Mar 21. No abstract available.

PMID:
30903870
39.

[Epithelial and melanotic skin tumors].

Fahmy J, Robert C.

Rev Prat. 2018 Nov;68(9):e363-e371. French. No abstract available.

PMID:
30869373
40.

The complexity of tumor shape, spiculatedness, correlates with tumor radiomic shape features.

Limkin EJ, Reuzé S, Carré A, Sun R, Schernberg A, Alexis A, Deutsch E, Ferté C, Robert C.

Sci Rep. 2019 Mar 13;9(1):4329. doi: 10.1038/s41598-019-40437-5.

41.

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600-mutated Metastatic Melanoma.

Yan Y, Wongchenko MJ, Robert C, Larkin J, Ascierto PA, Dréno B, Maio M, Garbe C, Chapman PB, Sosman JA, Shi Z, Koeppen H, Hsu JJ, Chang I, Caro I, Rooney I, McArthur GA, Ribas A.

Clin Cancer Res. 2019 Jun 1;25(11):3239-3246. doi: 10.1158/1078-0432.CCR-18-0720. Epub 2019 Mar 1.

PMID:
30824584
42.

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.

Lebbé C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P, Menzies AM, Eigentler T, Ascierto PA, Smylie M, Schadendorf D, Ajaz M, Svane IM, Gonzalez R, Rollin L, Lord-Bessen J, Saci A, Grigoryeva E, Pigozzo J.

J Clin Oncol. 2019 Apr 10;37(11):867-875. doi: 10.1200/JCO.18.01998. Epub 2019 Feb 27.

43.

Long-Term Safety and Efficacy of Single or Repeated Intra-Articular Injection of Allogeneic Neonatal Mesenchymal Stromal Cells for Managing Pain and Lameness in Moderate to Severe Canine Osteoarthritis Without Anti-inflammatory Pharmacological Support: Pilot Clinical Study.

Cabon Q, Febre M, Gomez N, Cachon T, Pillard P, Carozzo C, Saulnier N, Robert C, Livet V, Rakic R, Plantier N, Saas P, Maddens S, Viguier E.

Front Vet Sci. 2019 Feb 5;6:10. doi: 10.3389/fvets.2019.00010. eCollection 2019.

44.

Neurotoxicity induced by targeted therapies in patients treated for metastatic melanoma.

Velter C, Libenciuc C, Routier E, Mateus C, Fahmy J, Ghoufi L, Lambotte O, Not A, Cauquil C, Claveau S, Claveau J, Robert C.

Eur J Cancer. 2019 Apr;111:8-11. doi: 10.1016/j.ejca.2019.01.017. Epub 2019 Feb 22. No abstract available.

PMID:
30798086
45.

Mitochondrial myopathy associated with anti-programmed cell death 1 therapy.

Ibrahim T, Adam C, Routier E, Slama A, Robert C.

Eur J Cancer. 2019 Mar;110:71-73. doi: 10.1016/j.ejca.2019.01.001. Epub 2019 Feb 14. No abstract available.

PMID:
30772655
46.

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph R, Weber JS, Dronca R, Mitchell TC, Patnaik A, Zarour HM, Joshua AM, Zhao Q, Jensen E, Ahsan S, Ibrahim N, Ribas A.

Ann Oncol. 2019 Apr 1;30(4):582-588. doi: 10.1093/annonc/mdz011.

47.

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.

Robert C, Flaherty K, Nathan P, Hersey P, Garbe C, Milhem M, Demidov L, Mohr P, Hassel JC, Rutkowski P, Dummer R, Utikal J, Kiecker F, Larkin J, D'Amelio A Jr, Mookerjee B, Schadendorf D.

Eur J Cancer. 2019 Mar;109:61-69. doi: 10.1016/j.ejca.2018.12.015. Epub 2019 Jan 25.

PMID:
30690294
48.

IPSIM-Web, An Online Resource for Promoting Qualitative Aggregative Hierarchical Network Models to Predict Plant Disease Risk: Application to Brown Rust on Wheat.

Robin MH, Bancal MO, Cellier V, Délos M, Felix I, Launay M, Magnard A, Olivier A, Robert C, Rolland B, Sache I, Aubertot JN.

Plant Dis. 2018 Mar;102(3):488-499. doi: 10.1094/PDIS-12-16-1816-SR. Epub 2017 Nov 21.

PMID:
30673480
49.

IgG4 related orbit disease - An unusual cause of an orbital mass.

Chidambaram VA, Anita CSY, Robert C, Garry C.

Med J Malaysia. 2018 Dec;73(6):415-417.

50.

[What's new in oncodermatology?]

Robert C.

Ann Dermatol Venereol. 2018 Dec;145 Suppl 7:VIIS40-VIIS46. doi: 10.1016/S0151-9638(18)31288-2. Review. French.

PMID:
30583756

Supplemental Content

Loading ...
Support Center